Malignancies in HIV-infected patients. descriptive study of 129 cases between 1993 and 2010;Neoplasias en pacientes con infección por vih. estudio descriptivo de 129 casos en el período 1993-2010

Revista Chilena de Infectologia

Volumn 30, Issue 2, 2013, Pages

  Meijide, Héctor ^a   Mena, Alvaro ^a   Pernas, Berta ^a   Castro, Ángeles ^a   López, Soledad ^a   Vázquez, Pilar ^a   Bello, Laura ^a   Baliñas, Josefa ^a   Rodríguez Martínez, Guillermo ^a   Pedreira, José D ^a  

^a UNIVERSITY OF A CORUÑA   (Spain)

Author keywords

AIDS; Cancer; HIV; Malignancy

Indexed keywords

ADULT; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; COMPLICATION; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; HUMAN; MALE; MIDDLE AGED; NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDY; SPAIN; SURVIVAL;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; SPAIN; SURVIVAL ANALYSIS;

EID: 84878097605     PISSN: 07161018     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Anonimous. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992; 41: 119. [Links]
2. Long J L, Engels E A, Moore R D, Gebo K A. Incidence and outcomes of malignancy in the HAART era in an urban cohort of HIV-infected individuals. AIDS 2008; 22: 489-96. [Links]
3. Engels E A, Pfeiffer R M, Goedert J J, Virgo P, McNeel T, Scoppa S M, et al. Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS 2006; 20: 1645-54. [Links]
4. Harvard Report on Cancer Prevention. Volume 1: Causes of human cancer. Cancer Causes Control 1996; 7 (suppl 1): S3-59. [Links]
5. Nutankalva L, Wutoh A K, McNeil J, Frederick W R, Reddy R B, Daftary M, et al. Malignancies in HIV: pre- and post-highly active antiretroviral therapy. J Natl Med Assoc 2008; 100: 817-20. [Links]
6. Nuñez M. Hepatotoxicity of antiretrovirals: Incidence, mechanisms and management. J Hepatol 2006; 44: S132-9. [Links]
7. Samaras K. Metabolic consequences and therapeutic options in highly active antiretroviral therapy in human immunodeficiency virus-1 infection. J Antimicrob Chemother 2008; 61: 338-45. [Links]
8. Barbaro G, Barbarini G. HIV infection and cancer in the era of highly active antiretroviral therapy (review). Oncol Rep 2007; 17: 1121-6. [Links]
9. Davis A T, Chakraboryty H, Flowers K, Mosunjac M V. Cervical dysplasia in women infected with the human immunodeficiency virus (HIV): A correlation with HIV viral load and CD4 count. Gynecol Oncol 2001; 80: 350-4. [Links]
10. Ellerbrock T V, Chiasson M A, Bush T J, Sun X W, Sawo D, Brudney K, et al. Incidence of cervical squamous intraepithelial lesions in HIV-infected woman. JAMA 2000; 283: 1031-7. [Links]
11. Lomalisa P, Smith T, Guidozzi F. Human immunodeficiency virus infection and invasive cervical cancer in South Africa. Gynecol Oncol 2000; 77: 460-3. [Links]
12. Gichangi P B, Bwayo J, Estambale B, De Vuyst H, Ojwang S, Rogo K, et al. Impact of HIV infection on invasive cervical cancer in Kenyan women. AIDS 2003; 17: 1963-8. [Links]
13. Leitao Jr M M, White P, Cracchiolo B. Cervical cancer in patients infected with the human immunodeficiency virus. Cancer 2008; 112: 2683-9. [Links]
14. Gates A E, Kaplan L D. AIDS malignancies in the era of highly active antiretroviral therapy. Oncology 2002; 16: 657-65. [Links]
15. Spano J P, Atlan D, Breau J L, Farge D. AIDS and non- AIDS-related malignancies: a new vexing challenge in HIV positive patients. Pt I: Kaposi's sarcoma, non-Hodgkin's lymphoma, and Hodgkin's lymphoma. Eur J Intern Med 2002; 13: 170-9. [Links]
16. Ambinder R F. Epstein-Barr virus associated lymphoproliferations in the AIDS setting. Eur J Cancer 2001; 37: 1209-16. [Links]
17. Glaser S L, Lin R J, Stewart S L, Ambinder R F, Jarrett R F, Brousset P, et al. Epstein-Barr virus associated Hodgkin's disease: epidemiologic characteristics in international data. Int J Cancer 1997; 70: 375-82. [Links]
18. Clifford G M, Rickenbach M, Polesel J. Influence of HIV-related immunodeficiency on the risk of hepatocellular carcinoma. AIDS 2008; 22: 2135-41. [Links]
19. Giordano T P, Kramer J R, Souchek J, Richardson P, El-Serag HB. Cirrhosis and hepatocellular carcinoma in HIV infected veterans with and without the hepatitis C virus: a cohort study, 1992-2001. Arch Intern Med 2004; 164: 2349-54. [Links]
20. Spano J P, Atlan D, Breau J L, Farge D. AIDS and non- AIDS-related malignancies: a new vexing challenge in HIV positive patients. Pt II: Cervical and anal squamous epithelial lesions, lung cancer, testicular germ cell cancers, and skin cancers. Eur J Intern Med 2002; 13: 227-32. [Links]
21. Grulich A E, van Leeuwen M T, Falster M O, Vajdic C M. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007; 370: 59-67. [Links]
22. Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, et al. A review of human carcinogens-pt B: biological agents. Lancet Oncol 2009; 10: 321-2. [Links]
23. Parkin D M, Bray F. Chapter 2: The burden of HPV-related cancers. Vaccine 2006; 24 (Suppl 3): 11-25. [Links]
24. de Sanjosè S, Palefsky J. Cervical and anal HPV infection in HIV positive women and men. Virus Res 2002; 89: 210-1. [Links]
25. Minkoff H, Ahdieh L, Massad LS, Anastos K, Watts DH, Melnick S, et al. The effect of highly active antiretroviral therapy on cervical cytologic changes. AIDS 2001; 15: 2157-64. [Links]
26. Heard I, Tassie J M, Kazatchkine M D, Orth G. Highly active antiretroviral therapy enhances regression of cervical intraepithelial neoplasia in HIV-seropositive women. AIDS 2002; 16: 1799-802. [Links]
27. Grasso M A, Lodini S, Mastrorilli E, et al. Human papillomavirus infection and associated cervical disease in human immunodeficiency virus-infected women: effect of highly active antiretroviral therapy. J Infect Dis 2001; 184: 547-51. [Links]
28. Palefsky J. Anal squamous intraepithelial lesions: relation to HIV and human papillomavirus infection. J Acquir Immune Defic Syndr 1999; 21 (suppl 1): S42-8. [Links]
29. Palefsky J M, Holly E A, Ralston M L, Da Costa M, Greenblatt RM. Prevalence and risk factors for anal papillomavirus infection in human immunodeficiency virus (HIV)-positive and high-risk HIV-negative women. J Infect Dis 2001; 183: 383-91. [Links]
30. Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, d'Arminio Monforte A, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003; 362: 22-9. [Links]
31. Tumbarello M, Rabagliati R, De Gaetano Donati K, Bertagnolio S, Tamburrini E, Tacconelli E et al. Older HIV-positive patients in the era of highly active antiretroviral therapy: changing of a scenario. AIDS 2003;17: 128-31. [Links]
32. Jerico C, Knobel H, Sorli ML, Montero M, Guelar A, Pedro-Botet J. Prevalence of cardiovascular risk factors in HIV-infected patients. Rev Clin Esp 2006; 206: 556-9. [Links]
33. Informe VIH-SIDA en Galicia. Diagnósticos de infección polo VIH (2004-2008); Casos de SIDA (1984-2008). Consellería de Sanidade, Dirección Xeral de Saúde Pública e Planificación. 2009. Xunta de Galicia. Santiago de Compostela. [Links]
34. Pradier C, Carrieri M, Piche M, Rosenthal E, Dellamonica P, Serraino D. HCV infection and cancer risk among HIV-infected individuals. Infection 2003; 3: 194-6. [Links]
35. Berdimo R, Chen R Y, Accortt N A, Raper J L, Linn C, Alison J J, et al. Trends in AIDS-defining and non-AIDS defining malignancies among HIV-infected patients: 1989-2002. Clin Infect Dis 2004; 39: 1380-4. [Links]
36. Bonnet F, Lewden C, May T, Heripret L, Jougla E, Bevilacqua S, et al. Malignancy-related causes of death in human inmunodeficiency virus-infected patients in the era of highly active antiretroviral therapy. Cancer 2004; 101: 317-24. [Links]
37. Crum N F, Riffenburbh R H, Wegner S, Agan B K, Tasker S A, Spooner K M, et al. Comparisons of causes of death and mortality rates among HIV-infected persons: Analysis of teh pre-, early, and late HAART eras. J Acquir Immune Defic Syndr 2006; 41: 194-200. [Links]
38. Frish M, Biggar R J, Engels E A, Goedert, AIDS-Cancer Match Registry Study Group. Associaton of cancer with AIDS- related immunosuppresion in adults. JAMA 2001; 285: 1736-45. [Links]
39. Galceran J, Marcos-Gragera R, Soler M, Romaguera A, Ameijide A, Izquierdo A, et al. Cancer incidence in AIDS patients in Catalonia, Spain. Eur J Cancer 2007; 43: 1085-61. [Links]
40. Ramirez-Olivencia G, Valencia-Ortega ME, Martin-Carbonero L, Moreno-Celda V, Gonzalez-Lahoz J. Tumores en pacientes con infección por el virus de la inmunodeficiencia humana: estudio de 139 casos. Med Clin (Bar) 2009; 133: 729-35. [Links]
41. Tirelli U S M, Sandri S, Serraino D, Gobitti C, Fasan M, Sinicco A, et al. Lung carcinoma in 36 patients with human immunodeficiency virus infection. The Italian Cooperative Group on AIDS and Tumors. Cancer 2000; 88: 563-9. [Links]
42. Bower M, Powles T, Nelson M, Shah P, Cox S, Mandelia S, et al. HIV-related lung cancer in the era of HAART. AIDS 2003; 17: 371-75. [Links]
43. Brau N, Fox RK, Xiao P, Marks K, Nakvi Z, Taylor L E, et al. Presentation and outcome of hepatocellular carcinoma in HIV infected patients: A US-Canadian multicenter study. J Hepatol 2007; 47: 527-37. [Links]
44. Giordano T P, Kramer J R, Souchek J, Richardson P, El-Serag H B. Cirrhosis and hepatocellular carcinoma in HIV infected veterans with and without the hepatitis C virus: A cohort study, 1992-2001. Arch Intern Med 2004; 164: 2349-54. [Links]
45. Parisi S G, Cruciani M, Scaggiante R, Boldrin C, Andreis S, Dal Bello F, et al. Anal and oral human papillomavirus infection in HIV-infected subjects in northern Italy: a longitudinal cohort study among men who have sex with men. BMC Infect Dis 2011; 11: 150. [Links]
46. Crum-Cianflone N, Hullsiek KH, Marconi V, Weintrob A, Ganesan A, Barthel RV, et al. Trends in the incidence of cancers among HIV-infected persons and the impact of antiretroviral therapy: a 20-years cohort study. AIDS 2009; 23: 41-50. [Links]
47. Baker J V, Peng G, Rapkin J, Abrams D I, Silverberg M J, MacArthur R D, et al. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). CD4 count and risk of non-AIDS diseases following initial treatment for HIV infection. AIDS 2008; 22: 841-848. [Links]
48. Prosperi MC, Cozzi-Lepri A, Castagna A, Mussini C, Murri R, Giacometti A, et al. Incidence of malignancies in HIV-infected patients and prognostic role of current CD4 cell count: evidence from a large Italian cohort study. Clin Infect Dis 2010; 50: 1316-21. [Links]
49. El Sadr W M, Lundgren J D, Neaton J D, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355: 2283-96. [Links]
50. Powles T, Robinson D, Stebbing J, Shamash J, Nelson M, Gazzard B, et al. Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection. J Clin Oncol 2009; 27: 884-90. [Links]